VerImmune

Baltimore, United States

VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.

$4.5M raised

Sep 2024

Seed

Top Investors

National Science FoundationGaingelsUlu VenturesMana VenturesFosun Pharma

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has VerImmune raised?

VerImmune has raised $4.5M in total funding. The most recent round was Seed. The last funding was announced in September 2024.

Who are VerImmune's investors?

VerImmune's investors include National Science Foundation, Gaingels, Ulu Ventures, Mana Ventures, Fosun Pharma.

Where is VerImmune headquartered?

VerImmune is headquartered in Baltimore, United States.

What does VerImmune do?

VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.

What stage is VerImmune at?

VerImmune is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 23, 2024.

MLA

"VerImmune — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/verimmune. Accessed June 3, 2026.

APA

VCBacked. (2024). VerImmune — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/verimmune

Wikipedia (cite web)

{{cite web |title=VerImmune — Funding & Investors |url=https://www.vcbacked.co/company/verimmune |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 23, 2024.